Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …

Ferroptosis, a cell death process driven by iron-dependent phospholipid peroxidation, has
been implicated in various diseases. There are two major surveillance mechanisms to …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Despite being the hallmark of cancer that is responsible for the highest number of deaths,
very little is known about the biology of metastasis. Metastatic disease typically manifests …

Breast cancer is the most common cancer and the deadliest among women worldwide.
Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen …

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Drug resistance represents a major obstacle in cancer management, and the mechanisms
underlying stress adaptation of cancer cells in response to therapy-induced hostile …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

Cancer cells undergo metabolic reprogramming and switch to a 'glycolysis-
dominant'metabolic profile to promote their survival and meet their requirements for energy …